Gastrointestinal Pathology and Liver Metastasis: A Case-Based Approach to Diagnosis, 1st Edition

Part 1: Esophagus, 1
Inflammatory Disorders
1.1 Eosinophilic Esophagitis Versus Reflux Esophagitis
1.2 Lymphocytic Esophagitis Versus Candida Esophagitis Versus Lichen Planus Esophagitis
1.3 Candida Esophagitis Versus Other Neutrophil-Predominant Esophagitis
1.4 Viral Esophagitis Versus Pill and Corrosive Esophagitis
1.5 Epidermoid Metaplasia Versus Glycogenic Acanthosis
1.6 Melanosis or Melanocytosis (“Brown” Esophagus) Versus Acute Necrosis (“Black” Esophagus)
Glandular Dysplasia and Carcinoma
1.7 Columnar-Lined Esophagus Versus Barrett’s Esophagus
1.8 Multilayered Epithelium Versus Barrett’s Esophagus
1.9 Ancillary Stains for the Diagnosis of Barrett’s Esophagus
1.10 Barrett’s Esophagus Versus Carditis With Intestinal Metaplasia
1.11 Reactive Changes Versus Dysplasia (Including “Crypt Dysplasia”) in Barrett’s Esophagus
1.12 Low-Grade Versus High-Grade Conventional Dysplasia
1.13 Conventional Versus Foveolar Dysplasia
1.14 p53 Immunohistochemistry for Diagnosis of Dysplasia in Barrett’s Esophagus
1.15 High-Grade Dysplasia Versus Intramucosal Adenocarcinoma
1.16 Early Adenocarcinoma Reporting in Endoscopic Mucosal Resection and Endoscopic Submucosal Dissection Specimens
1.17 Esophageal Adenocarcinoma Variants
Squamous Dysplasia and Carcinoma
1.18 Grading and Management of Squamous Dysplasia
1.19 Typical and Variant Squamous Cell Carcinoma
Uncommon and Rare Esophageal Tumors and Therapy-Related Changes
1.20 Giant Fibrovascular Polyp Versus Atypical Lipomatous Tumor
1.21 Leiomyoma Versus Granular Cell Tumor
1.22 Poorly Differentiated and Undifferentiated Esophageal Carcinomas
1.23 Diagnostic Challenges in Post-neoadjuvant Esophageal Cancer Resection Specimens
1.24 Esophageal Adenocarcinoma Versus Salivary Gland–Type Tumors
1.25 Primary Versus Secondary Esophageal Carcinomas
Part 2: Stomach
Benign Conditions
2.1 Normal Stomach Versus Chronic Gastritis
2.2 Chronic Gastritis Versus Reactive Gastropathy
2.3 Helicobacter Pylori Gastritis: To Stain or Not to Stain
2.4 Autoimmune Gastritis Versus Helicobacter Gastritis
2.5 Iron Pill Gastropathy Versus Other Gastric Siderosis
2.6 Doxycycline Injury Versus Nonspecific Erosion
2.7 Lanthanum Injury Versus Other Histiocytic Infiltration
2.8 Lymphocytic Versus Collagenous Gastritis
2.9 Gastric Biopsy With Increase in Eosinophils
2.10 Acute Gastritis With Ulcer Versus Cytomegalovirus Gastritis
2.11 Acute Gastritis With Ulcer Versus Adenovirus Gastritis
2.12 Phlegmonous Gastritis
2.13 Chronic Gastritis With Intestinal Metaplasia: To Type or Not to Type
2.14 Chronic Gastritis With Reactive Changes Versus Intestinal-Type Dysplasia
2.15 Chronic Gastritis With Reactive Changes Versus Foveolar Dysplasia
2.16 High-Grade Dysplasia Versus Intramucosal
Adenocarcinoma
Polyps
2.17 Hyperplastic Polyp Versus Fundic Gland Polyp
2.18 Hyperplastic Polyp With Dysplasia Versus Intestinal-Type Adenoma
2.19 Pyloric Gland Adenoma Versus Foveolar-Type Adenoma
2.20 Oxyntic Gland Adenoma Versus Other Adenomas
2.21 Hyperplastic Polyp Versus Peutz-Jeghers Polyp
2.22 Multiple Fundic Polyps Versus Gastric Adenocarcinoma and Proximal Polyposis of the Stomach
Malignant Epithelial Tumors
2.23 Gastric Adenocarcinoma: Intestinal Versus Diffuse Type
2.24 Lymphocyte-Rich/Epstein-Barr Virus-Positive Versus Mismatch Repair Deficient Adenocarcinoma
2.25 Hepatoid Carcinoma Versus Poorly-Differentiated Adenocarcinoma
2.26 Enteroblastic Adenocarcinoma Versus Conventional Adenocarcinoma
2.27 Signet Ring Cell Carcinoma Versus Pseudo Signet Ring Cells
2.28 Signet Ring Cell Carcinoma: Sporadic Versus Familial
2.29 Signet Ring Cell Carcinoma: Primary Versus Metastatic
2.30 Sarcomatoid Carcinoma Versus Sarcoma
2.31 Gastroblastoma Versus Adenocarcinoma
2.32 Gastric Adenocarcinoma With HER2 Staining
2.33 Gastric Adenocarcinoma With Programmed Cell Death Ligand 1 Staining
2.34 Well-Differentiated Neuroendocrine Tumor in Autoimmune Gastritis (Type 1) Versus Neuroendocrine Hyperplasia
2.35 Well-Differentiated Neuroendocrine Tumor: Sporadic (Type 3) Versus Other Types (Types 1 and 2) and Neuroendocrine Carcinoma
Part 3: Small Intestine
Benign Conditions
3.1 Gastric Heterotopia Versus Neoplasm
3.2 Pediatric Small Intestinal Biopsies in Intractable Diarrhea
3.3 Small Bowel Disorders: Celiac Disease and Mimics
3.4 Small Bowel Infection: Protozoal, Microsporidial, Viral
3.5 Macrophage Infiltrates: Infectious Versus Non-Infectious Etiologies
3.6 Heterotopic Pancreas Versus Neoplasm
3.7 Active Ileitis With Crystals Versus Crohn’s Disease
Polyps
3.8 Adenoma With High-Grade Dysplasia Versus Invasive Adenocarcinoma
3.9 Pyloric Gland Adenoma Versus Brunner Gland Hamartoma
Tumors
3.10 Dystrophic Fat Versus Adenocarcinoma
3.11 Well-Differentiated Neuroendocrine Tumor Versus Neuroendocrine Carcinoma
3.12 Multilocular Peritoneal Inclusion Cyst Versus Malignant Mesothelioma
3.13 Gangliocytic Paraganglioma Versus Well-Differentiated Neuroendocrine Tumor of the Small Intestine
3.14 Ampullary Adenocarcinoma (pT2 Vs pT3)
3.15 Small Intestinal Adenocarcinoma Versus Metastatic Adenocarcinoma
Part 4: Appendix
Benign Conditions
4.1 Acute Appendicitis With Diverticulitis Versus Low-Grade Appendiceal Mucinous Neoplasm
4.2 Sessile Serrated Adenoma Versus Mucosal Hyperplasia
4.3 Benign Subserosal Glands (Endosalpingiosis) Versus Adenocarcinoma
Malignant Tumors
4.4 Low-Grade Appendiceal Mucinous Neoplasm Versus Appendiceal Adenoma
4.5 Low-Grade Appendiceal Mucinous Neoplasm Versus Distended Appendix With Mucin
4.6 Low-Grade Appendiceal Mucinous Neoplasm With Serosal Acellular Mucin and Other Risk Factors in Low-Grade Appendiceal Mucinous Neoplasm
4.7 Low-Grade Appendiceal Mucinous Neoplasm Versus High-Grade Appendiceal Mucinous Neoplasm
4.8 Mucinous Carcinoma Peritonei (Pseudomyxoma Peritonei), Low Grade (Grade 1) Versus High Grade (Grade 2)
4.9 Mucinous Carcinoma Peritonei (Pseudomyxoma Peritonei), Grade 2 Versus Grade 3
4.10 Goblet Cell Adenocarcinoma Versus Neuroendocrine Neoplasms and Conventional Adenocarcinoma
4.11 Appendiceal Neuroendocrine Tumor: Low- Versus High-Risk Features
4.12 Tubular Neuroendocrine Tumor Versus Adenocarcinoma

Sanjay Kakar, MD, Professor of Pathology, Chief of Gastrointestinal and Hepatobiliary Pathology Service, University of California, San Francisco in San Francisco, California, Ryan M. Gill, MD, PhD, Professor, Department of Pathology, University of California, San Francisco School of Medicine, San Francisco, California, USA and Amitabh Srivastava, MD, Department of Pathology, Brigham and Women’s Hospital, Boston, Massachusetts, USA